Kathleen A McGinnis1, Amy C Justice1,2, Richard D Moore3, Michael J Silverberg4, Keri N Althoff3, Maile Karris5, Viviane D Lima6, Heidi M Crane7, Michael A Horberg8, Marina B Klein9, Stephen J Gange3, Kelly A Gebo3, Angel Mayor10, Janet P Tate1,11. 1. Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA. 2. Yale Schools of Medicine and Public Health, New Haven, Connecticut, USA. 3. Johns Hopkins University, Baltimore, Maryland, USA. 4. Kaiser Permanente Northern California, Oakland, California, USA. 5. University of California, San Diego, San Diego, California, USA. 6. University of British Columbia, Vancouver, Canada. 7. University of Washington, Seattle, Washington, USA. 8. Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA. 9. McGill University, Montreal, Quebec, Canada. 10. Universidad Central del Caribe, Bayamon, Puerto Rico, USA. 11. Yale School of Medicine, New Haven, Connecticut, USA.
Abstract
BACKGROUND: The updated Veterans Aging Cohort Study (VACS) Index 2.0 combines general and human immunodeficiency virus (HIV)-specific biomarkers to generate a continuous score that accurately discriminates risk of mortality in diverse cohorts of persons with HIV (PWH), but a score alone is difficult to interpret. Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), we translate VACS Index 2.0 scores into validated probability estimates of mortality. METHODS: Because complete mortality ascertainment is essential for accurate calibration, we restricted analyses to cohorts with mortality from the National Death Index or equivalent sources. VACS Index 2.0 components were ascertained from October 1999 to April 2018. Mortality was observed up to March 2019. Calibration curves compared predicted (estimated by fitting a gamma model to the score) to observed mortality overall and within subgroups: cohort (VACS/NA-ACCORD subset), sex, age <50 or ≥50 years, race/ethnicity, HIV-1 RNA ≤500 or >500 copies/mL, CD4 count <350 or ≥350 cells/µL, and years 1999-2009 or 2010-2018. Because mortality rates have decreased over time, the final model was limited to 2010-2018. RESULTS: Among 37230 PWH in VACS and 8061 PWH in the NA-ACCORD subset, median age was 53 and 44 years; 3% and 19% were women; and 48% and 39% were black. Discrimination in NA-ACCORD (C-statistic = 0.842 [95% confidence interval {CI}, .830-.854]) was better than in VACS (C-statistic = 0.813 [95% CI, .809-.817]). Predicted and observed mortality largely overlapped in VACS and the NA-ACCORD subset, overall and within subgroups. CONCLUSIONS: Based on this validation, VACS Index 2.0 can reliably estimate probability of all-cause mortality, at various follow-up times, among PWH in North America. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
BACKGROUND: The updated Veterans Aging Cohort Study (VACS) Index 2.0 combines general and human immunodeficiency virus (HIV)-specific biomarkers to generate a continuous score that accurately discriminates risk of mortality in diverse cohorts of persons with HIV (PWH), but a score alone is difficult to interpret. Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), we translate VACS Index 2.0 scores into validated probability estimates of mortality. METHODS: Because complete mortality ascertainment is essential for accurate calibration, we restricted analyses to cohorts with mortality from the National Death Index or equivalent sources. VACS Index 2.0 components were ascertained from October 1999 to April 2018. Mortality was observed up to March 2019. Calibration curves compared predicted (estimated by fitting a gamma model to the score) to observed mortality overall and within subgroups: cohort (VACS/NA-ACCORD subset), sex, age <50 or ≥50 years, race/ethnicity, HIV-1 RNA ≤500 or >500 copies/mL, CD4 count <350 or ≥350 cells/µL, and years 1999-2009 or 2010-2018. Because mortality rates have decreased over time, the final model was limited to 2010-2018. RESULTS: Among 37230 PWH in VACS and 8061 PWH in the NA-ACCORD subset, median age was 53 and 44 years; 3% and 19% were women; and 48% and 39% were black. Discrimination in NA-ACCORD (C-statistic = 0.842 [95% confidence interval {CI}, .830-.854]) was better than in VACS (C-statistic = 0.813 [95% CI, .809-.817]). Predicted and observed mortality largely overlapped in VACS and the NA-ACCORD subset, overall and within subgroups. CONCLUSIONS: Based on this validation, VACS Index 2.0 can reliably estimate probability of all-cause mortality, at various follow-up times, among PWH in North America. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Entities:
Keywords:
HIV; VACS Index 2.0; calibration; mortality
Authors: Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore Journal: Int J Epidemiol Date: 2007-01-08 Impact factor: 7.196
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: Shawn L Fultz; Melissa Skanderson; Larry A Mole; Neel Gandhi; Kendall Bryant; Stephen Crystal; Amy C Justice Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Lesley S Park; Janet P Tate; Keith Sigel; Sheldon T Brown; Kristina Crothers; Cynthia Gibert; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Roger J Bedimo; Amy C Justice; Robert Dubrow Journal: Ann Intern Med Date: 2018-06-12 Impact factor: 25.391
Authors: Cherise Wong; Stephen J Gange; Richard D Moore; Amy C Justice; Kate Buchacz; Alison G Abraham; Peter F Rebeiro; John R Koethe; Jeffrey N Martin; Michael A Horberg; Cynthia M Boyd; Mari M Kitahata; Heidi M Crane; Kelly A Gebo; M John Gill; Michael J Silverberg; Frank J Palella; Pragna Patel; Hasina Samji; Jennifer Thorne; Charles S Rabkin; Angel Mayor; Keri N Althoff Journal: Clin Infect Dis Date: 2018-04-03 Impact factor: 9.079
Authors: Robert S Hogg; Oghenowede Eyawo; Alexandra B Collins; Wendy Zhang; Shahab Jabbari; Mark W Hull; Viviane Dias Lima; Tareq Ahmed; Claire E Kendall; Keri N Althoff; Amy C Justice; Rolando Barrios; Jeannie Shoveller; Julio S G Montaner Journal: Lancet HIV Date: 2017-03-03 Impact factor: 12.767
Authors: Keri N Althoff; Aruna Chandran; Jinbing Zhang; Wendy Miranda Arevalo; Stephen J Gange; Timothy R Sterling; M John Gill; Amy C Justice; Frank J Palella; Peter F Rebeiro; Michael J Silverberg; Angel M Mayor; Michael A Horberg; Jennifer E Thorne; Charles S Rabkin; W Christopher Mathews; Marina B Klein; Elizabeth Humes; Jennifer Lee; Robert Hogg; Richard D Moore Journal: Am J Epidemiol Date: 2019-12-31 Impact factor: 4.897
Authors: Janet P Tate; Amy C Justice; Michael D Hughes; Fabrice Bonnet; Peter Reiss; Amanda Mocroft; Jacob Nattermann; Fiona C Lampe; Heiner C Bucher; Timothy R Sterling; Heidi M Crane; Mari M Kitahata; Margaret May; Jonathan A C Sterne Journal: AIDS Date: 2013-02-20 Impact factor: 4.177